Sunflower Bank NA Wealth Management Sells 4,675 Shares of Pfizer Inc. (NYSE:PFE)
Sunflower Bank NA Wealth Management cut its holdings in Pfizer Inc. (NYSE:PFE) by 8.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,104 shares of the biopharmaceutical company’s stock after selling 4,675 shares during the quarter. Pfizer makes up approximately 0.6% of Sunflower Bank NA Wealth Management’s holdings, making the stock its 25th largest holding. Sunflower Bank NA Wealth Management’s holdings in Pfizer were worth $1,839,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of PFE. State Street Corp grew its stake in shares of Pfizer by 0.3% in the first quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after purchasing an additional 830,299 shares during the last quarter. Maverick Capital Ltd. bought a new stake in Pfizer during the 1st quarter valued at approximately $297,000. APG Asset Management N.V. boosted its position in Pfizer by 129.4% during the 1st quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock valued at $227,038,000 after acquiring an additional 3,924,241 shares in the last quarter. Cox Capital Mgt LLC boosted its position in Pfizer by 4.1% during the 2nd quarter. Cox Capital Mgt LLC now owns 54,196 shares of the biopharmaceutical company’s stock valued at $1,772,000 after acquiring an additional 2,133 shares in the last quarter. Finally, Modus Advisors LLC boosted its position in Pfizer by 67.6% during the 2nd quarter. Modus Advisors LLC now owns 28,458 shares of the biopharmaceutical company’s stock valued at $931,000 after acquiring an additional 11,477 shares in the last quarter. 69.08% of the stock is currently owned by institutional investors.
PFE has been the topic of several research reports. SVB Leerink lifted their price objective on Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a research report on Wednesday, July 29th. UBS Group lifted their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. ValuEngine cut Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Royal Bank of Canada set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Friday, October 16th. Finally, Berenberg Bank began coverage on shares of Pfizer in a report on Tuesday, September 29th. They set a “hold” rating and a $38.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $39.81.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company had revenue of $11.80 billion during the quarter, compared to analyst estimates of $11.55 billion. During the same period in the previous year, the business earned $0.80 EPS. The firm’s revenue for the quarter was down 11.0% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.84 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a $0.38 dividend. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a yield of 3.98%. Pfizer’s payout ratio is currently 51.53%.
In other news, Director Ronald E. Blaylock acquired 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was bought at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the acquisition, the director now directly owns 4,000 shares in the company, valued at $154,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.08% of the stock is owned by insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What is an overbought condition?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.